Pancreatic Cancer Research

ResearcherLMU KlinikumActive in the last 2 years

Andrea Tannapfel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0711-7100; OpenAlex author ID A5063413978, A5108241140, A5122329303. Sources: OpenAlex.

Their work

Papers
24 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
85
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 1 paper · 2014: 3 papers · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 3 papers · 2026: 1 paper

Papers 24

  1. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  2. Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort. Co-author DOI 10.1159/000543997↗
  3. An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial. Co-author DOI 10.1186/s12943-025-02406-7↗
  4. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  5. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. Co-author DOI 10.1159/000538171↗
  6. Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry. Co-author DOI 10.1186/s12885-024-12995-z↗
  7. Impact of preoperative chemotherapy on surgical results in 139 patients with locally advanced pancreatic cancer. Co-author DOI 10.21037/hbsn-23-426↗
  8. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  9. Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription. Co-author DOI 10.1126/sciadv.adg5109↗
  10. The impact of resection margin distance on survival and recurrence in pancreatic ductal adenocarcinoma in a retrospective cohort analysis. Last author DOI 10.1371/journal.pone.0281921↗
  11. [Pathological processing in pancreatic ductal adenocarcinoma-What is new?] First author DOI 10.1007/s00104-022-01615-w↗
  12. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
  13. Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
  14. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin … Last author DOI 10.1371/journal.pone.0248633↗
  15. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  16. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  17. [Update of the S3 guidelines for pancreatic cancer. What is new for pathologists?]. Last author DOI 10.1007/s00292-012-1712-7↗
  18. A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer. Co-author DOI 10.1016/j.cgh.2014.02.038↗
  19. Ductal pancreatic adenocarcinoma. Co-author DOI 10.3238/arztebl.2014.0396↗
  20. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  21. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.26466↗
  22. [New S3 guidelines on exocrine pancreatic cancer]. Co-author DOI 10.1007/s00292-012-1638-0↗
  23. Rare solid tumors of the pancreas as differential diagnosis of pancreatic adenocarcinoma. Co-author DOI 10.6092/1590-8577/791↗
  24. [R classification and pancreatic ductal adenocarcinoma--R 0 is R 0]. Last author DOI 10.1055/s-0031-1281750↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Waldemar H. Uhl · 13 shared papers, 2011–2026 · strength 1.46
  2. Anke Reinacher‐Schick · 8 shared papers, 2018–2026 · strength 1.32
  3. Johanna B. Munding · 7 shared papers, 2011–2023 · strength 0.76
  4. Thomas Theodor Werner Seufferlein · 6 shared papers, 2014–2025 · strength 0.71
  5. Michael B. Ghadimi · 4 shared papers, 2019–2026 · strength 0.60
  6. Uwe A. Wittel · 4 shared papers, 2018–2026 · strength 0.59
  7. Phyllis F. Cheung · 4 shared papers, 2021–2025 · strength 0.52
  8. Jens Thomas Siveke · 4 shared papers, 2021–2025 · strength 0.52
  9. Thomas Jens Ettrich · 4 shared papers, 2018–2025 · strength 0.45
  10. Dirk Weyhe · 2 shared papers, 2021–2023 · strength 0.41
  11. Dennis Obonyo · 2 shared papers, 2021–2023 · strength 0.41
  12. Sabine Semrau · 2 shared papers, 2025–2026 · strength 0.40
  13. Rainer Fietkau · 2 shared papers, 2025–2026 · strength 0.40
  14. Dorota Łubgan · 2 shared papers, 2025–2026 · strength 0.40
  15. Markus Hecht · 2 shared papers, 2025–2026 · strength 0.40
  16. Henriette Golcher · 2 shared papers, 2025–2026 · strength 0.40
  17. Robert Grützmann · 2 shared papers, 2025–2026 · strength 0.40
  18. Dirk Waldschmidt · 2 shared papers, 2025–2026 · strength 0.40
  19. Helmut Oettle · 2 shared papers, 2025–2026 · strength 0.40
  20. Stefan Hubert Boeck · 2 shared papers, 2025–2026 · strength 0.40
  21. Alexander Kleger · 3 shared papers, 2019–2025 · strength 0.39
  22. Stephan A. Hahn · 5 shared papers, 2012–2023 · strength 0.39
  23. Jasmin Schuhbaur · 2 shared papers, 2023–2024 · strength 0.33
  24. Smiths Lueong · 3 shared papers, 2021–2023 · strength 0.33
  25. Manfred Paul Lutz · 2 shared papers, 2023–2025 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.